Bayer Stock's June Legal Crossroads: $7.25B Settlement Opt-Out Countdown Meets Jefferies' Split Scenario

Bayer shares drop 5% as Jefferies maintains Hold despite higher target; June brings pivotal Roundup settlement opt-out deadline and Supreme Court decision on glyphosate liability.

June shapes up as a month of reckoning for Bayer, and the market is already voting with its feet. The shares closed Friday at €36.42, shedding 3.55% on the day and 5.13% on the week, as investors weigh twin legal deadlines against a fresh but cautious analyst outlook. Jefferies lifted its price target to €40 from €25, yet kept a "Hold" rating — a reflection of the deep uncertainty that continues to overshadow any sum-of-parts optimism.

The new Jefferies analysis, led by pharma sector analyst Michael Leuchten, hinges on a sum-of-all-parts model that values Bayer at €45 per share in a base case. But the bank also sketches a bearish scenario: persistent legal headwinds could drag the stock to €30. That wide range explains why the analyst remains on the sidelines. "Bayer looks cheaper on paper, but the discount is justified," the note implies, pointing to the lack of near-term pipeline catalysts that might otherwise justify a full re-rating.

The legal calendar is what makes June so pivotal. On June 4, the 90-day opt-out window closes for the $7.25 billion Roundup class-action settlement that Bayer proposed in February. The deal, preliminarily approved by a Missouri judge in March, allows claimants to either participate, file objections, or opt out — and Bayer retains the right to walk away if too many choose the latter. The opt-out rate is therefore the single most important metric for the company's financial planning.

The settlement has already drawn fire. On May 21, lawyers in Missouri filed a formal objection, branding the proposal "grossly inadequate and unfair." A separate flashpoint is the so-called "futures subclass," which would automatically cover any U.S. resident who used Roundup before February 17, 2026 — including children and even unborn individuals. The structure has sparked ethical and legal pushback.

Meanwhile, a much bigger decision looms. The U.S. Supreme Court heard oral arguments on April 27 in Monsanto v. Durnell, a case that asks whether federal labeling laws preempt state-level warning claims on glyphosate. The EPA has consistently classified glyphosate as non-carcinogenic and approved Roundup's label without a cancer warning. JP Morgan expects a ruling by the end of June, and estimates that roughly 80% of outstanding glyphosate claims against Bayer would be affected. A favorable decision could effectively dismantle the litigation overhang without another settlement.

The operational picture offers some counterbalance. First-quarter revenue rose 4.1% on a currency-adjusted basis to €13.4 billion, while adjusted EBITDA climbed 9.0% to €4.45 billion. Full-year revenue guidance remains at €44.5–€46.5 billion. The free cash flow, however, tells a different story: it came in at negative €2.32 billion, compared with negative €1.53 billion a year earlier, driven by roughly €2.0 billion in settlement payouts for PCB and glyphosate cases.

On the pharma side, momentum has picked up. The FDA granted priority review to the cancer drug Sevabertinib and, within two days, also accepted Asundexian, a blood thinner, for accelerated review. A phase III trial for the PET/CT radiotracer Iod-124-Evuzamitide in cardiac amyloidosis hit its primary endpoints. These are positive signals, but Jefferies' Leuchten argues they don't yet constitute the kind of pipeline inflection that would justify taking a more aggressive stance.

The legal overhang isn't limited to glyphosate. New antitrust allegations in the U.S. concerning an alleged seed monopoly add another layer of uncertainty — costs that remain difficult to quantify. That ambiguity keeps the market cautious, and the stock's technical profile reflects the tug-of-war: at €36.42, Bayer sits below its 50-day moving average of €38.73 but still above the 200-day line at €35.63, a configuration that suggests a bruised sideways grind rather than a clear trend.

For income-focused investors, there is little comfort. The dividend for fiscal 2025 has been set at €0.11 per share, approved at the April 24 annual general meeting. It marks a continuation of the company's policy to pay only the legally required minimum for several years as it conserves liquidity. Earnings per share are estimated at €4.35 for 2026.

The next hard dates are now set: the opt-out deadline on June 4, the Supreme Court ruling later that month, and the final fairness hearing for the settlement on July 9. Each one carries implications worth billions. Until at least one of these milestones resolves in Bayer's favor, the stock will likely remain caught between a sum-of-parts that says €45 and a legal discount that pulls it toward €30.